Comparison of simultaneous integrated tumor bed boost and sequential boost during hypofractionated whole-breast irradiation after breast-conserving surgery

Dan‐Qiong Wang, Yuchun Song, Jing Hao, Hui Fang, Yong-Wen Song, Yueping Liu, Jing Jin, Shu‐Nan Qi, Yuan Yan Tang, Ning-Ning Lu, Bo Chen, Ning Li, Yirui Zhai, Wen‐Wen Zhang, Xin Liu, Siye Chen, Zhuanbo Yang, Guang-Yi Sun, Xu-Ran Zhao, Zihan Qiu, Ye‐Xiong Li, Shulian WangClinical 2025 · DOI

TL;DR

This study compares two radiotherapy boost techniques (simultaneous integrated boost - SIB, and sequential boost - SeB) for early breast cancer patients undergoing hypofractionated whole-breast irradiation (HF-WBI) after breast-conserving surgery. The findings suggest SIB is a safe and effective alternative to SeB, offering comparable outcomes and the significant advantage of a shorter treatment duration.

What Problem Does This Paper Address?

Following breast-conserving surgery for early breast cancer, adjuvant radiotherapy is crucial for reducing recurrence rates and improving survival. A key component of this radiotherapy is delivering a "boost" dose to the original tumor bed to further minimize the risk of local recurrence, as most recurrences occur in this area. Traditionally, this boost was delivered sequentially after the main whole-breast irradiation (SeB). However, with the advent of hypofractionated WBI (HF-WBI), which shortens the overall treatment course by delivering larger doses per fraction, the sequential boost can negate some of these time-saving benefits. The simultaneous integrated boost (SIB) technique aims to overcome this by delivering the boost dose concurrently with the WBI, potentially offering the advantages of HF-WBI without prolonging treatment. This paper addresses the question of whether SIB is as safe and effective as the established SeB when used with HF-WBI, particularly concerning survival, toxicity, and cosmetic outcomes.

Methods

This study retrospectively analyzed data from two prospective trials involving 1,132 patients with early-stage breast cancer (pT1-3 N0-3 MO) who underwent breast-conserving surgery and received HF-WBI. Of these, 775 patients received SIB, and 357 received SeB. Both groups received a standard dose of 43.5 Gy in 15 fractions to the whole breast and/or nodal regions. The SIB group received an additional 6 Gy in 15 fractions concurrently with the WBI, totaling 49.5 Gy. The SeB group received an additional 8.7 Gy in 3 fractions sequentially after the WBI.

The researchers compared several outcomes:

  • Survival Outcomes: Local control (LC), locoregional control (LRC), disease-free survival (DFS), overall survival (OS), and breast cancer-specific survival (BCSS).
  • Treatment-Related Toxicities: Assessed using the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0, focusing on grade 2 or higher toxicities.
  • Breast Cosmetic Outcomes: Evaluated using patient self-reported assessments (Harvard 4-point scale) before and after radiotherapy.

To account for baseline differences between the SIB and SeB groups (the SIB group had more patients with higher stage disease, lymphovascular invasion, and received more neoadjuvant chemotherapy), the researchers employed stabilized inverse probability of treatment weighting (IPTW) to create a more balanced comparison.

Datasets

The study utilized data from two prospective clinical trials conducted at a single institution:

  • A phase III randomized study (NCT01413269) for patients receiving HF-WBI with SeB (2010-2015).
  • A phase II prospective study (NCT03320421) for patients receiving HF-WBI with SIB (2016-2018).

The combined dataset comprised 1,132 patients. No new benchmarks were introduced; the study focuses on comparing two established radiotherapy techniques within the context of HF-WBI.

Key Insights and Ideas

  • SIB is a viable alternative to SeB: The study strongly supports SIB as a comparable alternative to SeB for HF-WBI, offering similar efficacy and safety profiles.
  • Time is of the essence: The primary advantage of SIB is its ability to shorten treatment duration without compromising outcomes. This is crucial for patient convenience, compliance, and potentially reducing healthcare costs.
  • Cosmetic outcomes are complex: While the SIB group reported better cosmetic outcomes, this difference appeared to predate radiotherapy, suggesting surgical techniques might play a larger role than the boost method itself in this specific cohort. However, the deterioration in cosmetic outcomes was comparable between groups, indicating SIB doesn't worsen this aspect.
  • Toxicity is manageable: Both SIB and SeB demonstrated low rates of severe (grade 2+) toxicities, with no significant differences observed between the groups for most adverse events. This is reassuring for patients considering SIB.

Key Results

  • Survival Outcomes: After IPTW adjustment, there were no statistically significant differences between SIB and SeB groups in 5-year rates for:
  • Local Control (LC): 97.8% vs. 97.8% (p=0.72)
    • Locoregional Control (LRC): 97.7% vs. 96.3% (p=0.33)
    • Disease-Free Survival (DFS): 94.2% vs. 93.1% (p=0.72)
    • Overall Survival (OS): 97.3% vs. 98.2% (p=0.32)
    • Breast Cancer-Specific Survival (BCSS): 98.1% vs. 98.2% (p=0.93)
  • Toxicity: No significant differences were found in grade 2 or higher toxicities (skin toxicity, pneumonitis, breast swelling, pain, lymphedema, shoulder mobility issues) between the SIB and SeB groups.
  • Cosmetic Outcomes: While the SIB group reported better overall cosmetic outcomes, the rate of cosmetic deterioration was comparable between the groups (9.8% for SIB vs. 7.6% for SeB, p=0.22).

Limitations and Future Work

The authors acknowledge several limitations:

  • Non-randomized design: The SIB group had a higher proportion of patients with more risk factors, necessitating the use of IPTW for statistical adjustment.
  • Treatment modality differences: The SIB group more frequently received IMRT/VMAT for their tumor bed boost, while the SeB group more often used electrons. This could introduce confounding factors.
  • Follow-up duration: Toxicity analyses were capped at 5 years due to the time-dependent nature of late effects. Longer follow-up is needed to fully assess long-term outcomes, particularly for cosmetic results.

Future work should focus on longer-term follow-up to confirm these findings and further investigate the dose-effect relationship of radiotherapy-related toxicities, especially concerning breast induration and cosmetic outcomes. Exploring the optimal dose parameters for SIB in different patient populations and with advanced treatment technologies remains an area for continued research.

Summary updated

Abstract

SIB is a viable alternative to SeB, offering comparable toxicity profiles and survival outcomes while shortening treatment duration. Longer follow-up is warranted to assess long-term outcomes.
BibTeX
@inproceedings{wang2025comparison,
  author = {Dan‐Qiong Wang and Yuchun Song and Jing Hao and Hui Fang and Yong-Wen Song and Yueping Liu and Jing Jin and Shu‐Nan Qi and Yuan Yan Tang and Ning-Ning Lu and Bo Chen and Ning Li and Yirui Zhai and Wen‐Wen Zhang and Xin Liu and Siye Chen and Zhuanbo Yang and Guang-Yi Sun and Xu-Ran Zhao and Zihan Qiu and Ye‐Xiong Li and Yu Tang and Shulian Wang},
  title = {{Comparison of simultaneous integrated tumor bed boost and sequential boost during hypofractionated whole-breast irradiation after breast-conserving surgery}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1016/j.ctro.2025.100967},
}
Figure